Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...
Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing ...
CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...
Dublin, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The "CRISPR Gene Editing in Infectious Diseases: Market Overview" report has been added to ResearchAndMarkets.com's offering. The report provides an overview ...
Sign up for CNN’s Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more. The United Kingdom ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
CRISPR, the gene-editing technology that has revolutionized biological research, is finally available as a medical treatment with regulatory approval. On December 8 the U.S. Food and Drug ...
When the genome-editing tool CRISPR is thought of as a potential medicine, the targets that first come to mind are diseases like sickle cell or other conditions caused by particular mutations. Use ...
Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval comes ...
(MENAFN- GlobeNewsWire - Nasdaq) CRISPR-based therapeutics present market opportunities in infectious diseases through genome disruption, host gene editing, and immune cell engineering. Key areas ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback